Four outstanding young Chinese scientists received the 2013 Scholar Award from the US Chinese Anti-Cancer Association and the National Foundation for Cancer Research

To facilitate and strengthen collaborations among cancer researchers and physicians in the United States and China, the US Chinese Anti-Cancer Association (USCACA) and the National Foundation for Cancer Research (NFCR) have established the Scholar Excellence Award for the USCACA-NFCR Scholar Exchange and Fellowship Program in Basic, Translational, and Clinical Studies. Since 2010, 10 young Chinese researchers and physicians have received the award for their outstanding achievements in cancer research accomplished while in the United States, as well as their continuing efforts in eradicating cancer after their return to China. This year, USCACA and NFCR selected 4 young scientists for their excellence in basic or clinical cancer research. Here, we are proud to introduce these 4 winners of the 2013 USCACA-NFCR Scholar Excellence Award: The ceremony of the fourth USCACA-NFCR Scholar Excellent Award in Guangzhou, China, November 9, 2013. Dr. Yan Sun at the Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Dr. Weiwei Yang at the Laboratory of Cancer Metabolism, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai; Dr. Chenfang Dong at the Department of Pathology, Zhejiang University School of Medicine, Hangzhou; and Dr. Haizhong Feng at the Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai. The awards were presented to these 4 awardees at the 3rd International Symposium on Oncology held at Baiyun Conference Center in Guangzhou during November 7-9, 2013. We have invited each of these four awardees to contribute a short essay summarizing their achievements in cancer research. As illustrated in their essays, these outstanding young scholars have received excellent training under their US mentors who are USCACA members. These talented young scientists have not only made impressive discoveries in the mechanisms underlying the causes or progression of human cancers, but also discovered new approaches for improving treatments for cancer patients. Our ultimate goal is to expedite novel cancer drug development by stimulating the translation of laboratory findings into novel cancer therapies, fostering collaborations in clinical cancer drug development, and sharing expert knowledge and medical practices between China and the United States.